ArticleScientific reports2025
Downregulation of EAAT-2 impairs chronic neuropathic pain via increasing of plasma glutamate after herpes zoster infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nomogram-Based Prediction Model for Postherpetic Neuralgia in Immunosuppressive Patients.Journal of clinical medicine · 2026Article
- The excitatory neurotransmitter glutamate and its receptors: the culprits behind neuropathic pain?Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Chronic neuropathic pain (CNP) is a debilitating complication of herpes zoster (HZ) with significant impact on quality of life. This study aimed to investigate the association between excitatory amino acid transporter 2 (EAAT-2) expression and plasma glutamate concentrations in HZ patients with CNP. This study was conducted with 102 consecutive patients diagnosed with HZ. Participants were divided into two groups: CNP (n = 51) and acute pain (ACP, n = 51). Pain severity was assessed using the Numerical Rating Scale. Blood samples were collected for genotype analysis, mRNA and protein extraction, and plasma glutamate measurement. EAAT-2 DNA genotyping was analyzed by polymerase chain reaction (PCR); EAAT-2 mRNA expression was analyzed by quantitative real-time PCR; EAAT-2 protein and glutamate levels were analyzed by enzyme-linked immunosorbent assay. The EAAT-2 DNA showed no significant difference in CNP and ACP patients. CNP patients exhibited lower EAAT-2 mRNA and protein levels compared to ACP patients. However, plasma glutamate levels were significantly elevated in the CNP patients. A correlation was observed between EAAT-2 protein concentration and plasma glutamate levels in the CNP group. This study demonstrates EAAT-2 mRNA downregulation, reduced EAAT-2 protein concentration, and elevated plasma glutamate levels play roles in CNP following HZ infection. These findings suggests that EAAT-2 may be a relevant target for further investigation in therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.